On Friday, in the course of current trade, Shares of JPMorgan Chase & Co. (NYSE:JPM), dropped -0.09%, and is now trading at $68.46.
JPMorgan Chase & Co., declared that it had accomplished the first-ever debt offering co-managed exclusively by a group of U.S. military veteran-owned broker-dealers. The $1.75 billion subordinated notes offering by JPMorgan Chase was co-managed by Academy Securities, CAVU Securities, Drexel Hamilton, Mischler Financial Group and Multi-Bank Securities. J.P. Morgan Securities LLC was the sole bookrunner of the offering.
The offering priced preceding to the Memorial Day holiday on May 21, 2015 and closed on May 29, 2015.
“This transaction is one instance of how JPMorgan Chase is assisting veteran-owned businesses grow. This tribute to the men and women who have served our great nation shows that JPMorgan Chase understands the value of doing business with military veterans,” said Ron Quigley, Head of Fixed Income Syndicate at Mischler Financial Group.
This transaction builds upon JPMorgan Chase’s other programs designed to assist position transitioning servicemembers, veterans and their families for success in their post-service lives through initiatives impacting employment, housing, and education and training.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
During an early morning trade, Shares of Citrix Systems, Inc. (NASDAQ:CTXS), gained 1.58%, and is now trading at $71.50.
Citrix Systems, issued the following statement in response to a letter to the Citrix Board of Directors from Elliott Administration Corp.
“Citrix has always maintained an ongoing dialogue with our shareholders, and we welcome their input. We will review Elliott’s suggestions and respond as we do with all shareholders who engage with us. The Citrix Board and administration team continually evaluate ideas to drive shareholder value and are committed to acting in the best interests of all our shareholders.”
Citrix Systems, Inc. provides virtualization, mobility administration, networking, and Software as a Service solutions worldwide. The company’s Enterprise and Service Provider division offers XenMobile Enterprise, a solution to manage mobile devices, apps, and data; XenDesktop, a desktop virtualization system that gives customers the flexibility to deliver desktops and applications as cloud services; Citrix XenApp that allows Windows applications to be delivered as cloud services to Android and iOS mobile devices, Macs, PCs, and thin clients; and Citrix Workspace Suite, a business mobility solution that delivers the user experience for any app or desktop.
Finally, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), lost -0.28% Friday.
Intrexon Corporation (XON), declared that it has determined the final distribution ratio regarding its formerly declared distribution of all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. (ZIOP) common stock on or about June 12, 2015, the distribution date, as a pro rata dividend on shares of Intrexon common stock, and on warrants to purchase shares of Intrexon common stock (“Warrants”), outstanding on June 4, 2015, the record date.
Based on the number of Intrexon shares outstanding and shares deliverable under Warrants as of the record date, holders of Intrexon common stock will receive 0.162203 shares of ZIOPHARM common stock in the distribution with respect to each outstanding share of Intrexon common stock they own at the close of business on the record date, and holders of Warrants will receive 0.162203 shares of ZIOPHARM common stock in the distribution with respect to each share of Intrexon common stock deliverable under the Warrants they hold at the close of business on the record date.
Fractional shares of ZIOPHARM common stock will not be distributed to Intrexon shareholders or Warrant holders. Instead, the fractional shares of ZIOPHARM common stock will be aggregated and sold back to ZIOPHARM, with the net proceeds distributed pro rata in the form of cash payments to Intrexon shareholders and Warrant holders who would otherwise receive ZIOPHARM fractional shares.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
